Clin Psychopharmacol Neurosci.  2016 Nov;14(4):345-350. 10.9758/cpn.2016.14.4.345.

Evaluation of Paraoxonase, Arylesterase and Malondialdehyde Levels in Schizophrenia Patients Taking Typical, Atypical and Combined Antipsychotic Treatment

• GüneÅŸ M
• Camkurt MA
• Bulut M
• Demir S
• IbiloÄŸlu
• Kaya MC
• Atlı A
• Kaplan I
• Sir A

• KMID: 2356158
• DOI: http://doi.org/10.9758/cpn.2016.14.4.345

Abstract

OBJECTIVE
Human serum paraoxonase (PON1) prevents lipids from peroxidation and functions as an antioxidant mechanism. Malonyldialdehyde (MDA) is the final product of lipid peroxidation and can be used as an indicator of oxidative stress. The aim of this study was to investigate PON1, MDA, and arylesterase (ARY) levels in schizophrenic patients who are taking typical, atypical, or combined (typical and atypical) antipsychotic drug treatment, with respect to those of healthy controls.
METHODS
We evaluated 41 patients (11 taking typical antipsychotics, 19 taking atypical antipsychotics, 11 taking combined anti-psychotics) and 43 healthy controls.
RESULTS
MDA levels were higher in schizophrenic patients taking typical antipsychotics compared with healthy controls (p=0.001). ARY levels were higher in patients taking atypical antipsychotics compared with healthy controls (p=0.005). PON1 activity was similar in all groups.
CONCLUSION
Our results indicate that treatment with typical antipsychotic drugs could be related to increased MDA levels; and antipsychotic medication may increase PON1 levels in schizophrenic patients.

Keyword

Paraoxonase; Arylesterase; Malondialdehyde; Schizophrenia; Antipsychotics; Treatment

MeSH Terms

Antipsychotic Agents
Aryldialkylphosphatase*
Humans
Lipid Peroxidation
Malondialdehyde*
Oxidative Stress
Schizophrenia*
Antipsychotic Agents
Aryldialkylphosphatase
Malondialdehyde